An interventional study of Central-line-associated bloodstream infection prevention bundle in Catheter-Related Bloodstream Infection and Healthcare-Associated Infection, sponsored by Peking University First Hospital. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Peking University First Hospital · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Cross Infection with a site in China — 3 open to participants now, 4 under way, none of them phase 3. Cross Infection · China.
Among the 11 studies in Cross Infection with a site in China, this one is the only one that started in 2024, is one of 7 with no phase, and was the 11th registered.
286 studies on the registry are indexed under Cross Infection; 48 are open to participants now.
Browse Cross Infection studies →3 of the 11 studies in Cross Infection with a site in China are open now. Recruiting first, the newest first:
The Hong Kong Polytechnic University · Sites in China, Hong Kong
Ages 18+ · Healthy volunteers
Capital Medical University · Sites in China
Ages 2+ · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 27 Cross Infection studies recruiting now, 22 (81%) set no upper age limit and 3 (11%) stop at 75 or younger; 6 take children under 18; 6 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2024.
This study's planned enrollment of 1,200 is above the median of 193 across 170 interventional studies indexed under Cross Infection.
Median enrollment 402 across the 8 interventional studies, 500 across the 3 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 11 have an industry lead sponsor. The 10 most frequent:
Peking University First Hospital is the lead sponsor of 393 studies on the registry; 188 are open to participants now.
Peking University First Hospital has 1 study filed under Cross Infection — fewer than ten, so there is no comparison to draw.
2 of the studies in Cross Infection with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07941856Peking University First HospitalA Mixed-Method Study for Implementation of Central Line-Associated Bloodstream Infection Control in Intensive Care Units | 2026-12 |
| NCT07280026The Hong Kong Polytechnic UniversityEffectiveness of an Edge AI-based Augmented Reality System for Hand Hygiene Training: a Multi-centre, Mixed-methods Cluster Randomised Controlled Trial | 2027-08-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies in Cross Infection with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phased mixed-method implementation study aiming to develop and evaluate a multi-component central-line-associated bloodstream infection (CLABSI) prevention bundle in three intensive-care units (Respiratory Intensive Care Unit, RICU; Surgical Intensive Care Unit, SICU; Neonatal Intensive Care Unit, NICU) at Peking University First Hospital. This study will first conduct pilot testing of the refined bundle in NICU, then scale-up implementation across all three ICUs. CLABSI incidence rate per 1000 central line-days is the primary outcome; bundle adherence rate and multi-dimensional implementation outcomes are secondary outcomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Single-group intervention, implementing multi-component CLABSI prevention bundle in NICU, RICU and SICU with phased roll-out
Behavioral: Central-line-associated bloodstream infection prevention bundle
A multi-component CLABSI prevention bundle with six core measures: (1) preferable insertion site selection, (2) hand hygiene, (3) maximum sterile barrier precautions, (4) catheter hub disinfection and insertion site care, (5) timely removal of non-essential catheters, and (6) implementation of a standardized checklist. The study adopts a phased implementation design: a pilot phase will first be conducted in NICU to test the bundle, identify implementation barriers, and refine local strategies; after optimization, the refined bundle will be rolled out across RICU, SICU and NICU. Local implementation teams will develop tailored action plans, monitor adherence, and iteratively optimize implementation strategies throughout the study.
CLABSI incidence rate
CLABSI cases per 1000 central-line-days, defined according to Centers for Disease Control and Prevention (CDC) National Healthcare Safety Network (NHSN) criteria. Calculated as number of CLABSI events divided by total central-line-days multiplied by 1000, collected prospectively in RICU, SICU and NICU.
Time frame: Baseline through intervention period, up to 36 months
Overall CLABSI prevention bundle adherence score
A composite adherence score calculated as the mean proportion of correctly performed elements across six core CLABSI-prevention bundle measures (hand hygiene, maximum sterile barrier precautions, preferable insertion site, disinfection and site care, nonessential catheter removal, and checklist completion), assessed by direct observation and chart review. The score is expressed as a single percentage ranging from 0% to 100%.
Time frame: Baseline through implementation period, up to 36 months
Acceptability of the CLABSI prevention intervention bundle
Acceptability will be assessed through semi-structured interviews with healthcare professionals involved in implementation to explore perceptions of whether the intervention bundle is agreeable and satisfactory in routine clinical practice. Findings will be reported as qualitative themes and categories.
Time frame: Entire study duration, up to 36 months
Fidelity of implementation of the intervention bundle - Quantitative assessment
The degree to which the intervention bundle is implemented as intended according to predefined implementation procedures, assessed by quantitative process indicators, case audits, and checklists. Fidelity will be reported as the proportion of predefined procedures correctly completed.
Time frame: Entire study duration, up to 36 months
Fidelity of implementation of the intervention bundle - Qualitative assessment
The degree to which the intervention bundle is implemented as intended, assessed through semi-structured interviews with implementation stakeholders. Qualitative findings regarding barriers and facilitators to implementation fidelity will be reported as themes.
Time frame: Entire study duration, up to 36 months
Feasibility of implementation of the intervention bundle
Feasibility will be assessed through semi-structured interviews with healthcare professionals to determine the extent to which the intervention bundle can be successfully implemented within participating intensive care units. Findings will be reported as qualitative themes describing barriers and facilitators to implementation.
Time frame: Entire study duration, up to 36 months
Sustainability of implementation of the intervention bundle - Quantitative assessment
The extent to which implementation of the intervention bundle is maintained over time, assessed using quantitative process indicators. Sustainability will be reported as the proportion of bundle elements continued in routine clinical practice.
Time frame: Entire study duration, up to 36 months
Sustainability of implementation of the intervention bundle - Qualitative assessment
The extent to which implementation of the intervention bundle is integrated into routine clinical practice over time, assessed through semi-structured interviews. Qualitative findings will be reported as themes.
Time frame: Entire study duration, up to 36 months
Plan to share: No — Individual-participant data will not be shared publicly because of patient privacy restrictions and local institutional data security requirements. Aggregated study results may be published in peer-reviewed journals.
No publications or documents are linked to this record.
Started Nov 2024 (actual). Primary completion is estimated for Dec 2026, 25 months after the start.
Of 58 non-industry interventional studies with no phase under Cross Infection, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 29. This study's planned 25 months is above that.
Counting every sponsor, half of 60 studies reached it within 16 months; a quarter within 7 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Peking University First Hospital →